Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
Rhea-AI Summary
Firefly (NASDAQ: AIFF) reported a >20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP scan volumes, ending 2025 with 99 commercial users and more than 10,800 EEG/ERP brain scans.
The company cited its acquisition of Evoke Neuroscience and deployment of NVIDIA L40S GPU acceleration as enablers for AI-driven biomarker discovery and progress toward an EEG/ERP-based foundation model of the human brain.
Positive
- Commercial footprint expanded >20-fold by end of 2025
- EEG/ERP scan volumes increased 33-fold to >10,800 scans
- Partner sites grew 1,880% year-over-year to 99 users
- Data scale growth of 3,227% in clinical assessments since end-2024
- NVIDIA L40S GPU deployed for accelerated EEG/ERP processing
Negative
- None.
Market Reaction – AIFF
Following this news, AIFF has gained 66.42%, reflecting a significant positive market reaction. Argus tracked a peak move of +65.0% during the session. Our momentum scanner has triggered 31 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.14. This price movement has added approximately $4M to the company's valuation. Trading volume is exceptionally heavy at 376.5x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
AIFF was down 3.52% while only one high‑affinity peer in momentum (CYN) moved up, and others showed flat or unspecified moves, pointing to stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | +5.5% | Stronger revenue, lower expenses, and reduced net loss after Evoke acquisition. |
| Sep 05 | Strategic partnership | Positive | +3.7% | HealingMaps partnership broadening access to EEG-based analytics across 2,500+ clinics. |
Recent positive operational and partnership news has coincided with positive one-day price reactions.
In late 2025, Firefly reported Q3 results showing revenue of $388,000, up sharply year over year, with operating expenses reduced to about $2.8 million and cash of roughly $4.3 million. A September 2025 partnership with HealingMaps expanded access to over 2,500 clinics using its FDA-510(k)-cleared EEG/ERP analytics platform. Both events saw positive 24-hour price reactions of 5.45% and 3.73%, respectively. Today’s update on commercial expansion and data growth builds on that trajectory of scaling EEG/ERP-driven brain health solutions.
Regulatory & Risk Context
An effective Form S-3 mixed shelf filed on Dec 3, 2025 registers up to $250,000,000 of securities, and a $7,434,266 at-the-market equity program has already been set up via a 424B5 prospectus, giving the company flexibility to issue common stock and other securities for working capital and general corporate purposes.
Market Pulse Summary
The stock is surging +66.4% following this news. A strong positive reaction aligns with recent news where operational milestones and partnerships coincided with gains of 3–5%. The reported >20-fold footprint expansion and >10,800 EEG/ERP scans materially increase Firefly’s data asset, supporting its brain foundation model ambitions. However, investors also contended with an active $250,000,000 shelf and a $7,434,266 ATM program that allowed additional equity issuance, which could influence longer-term trading dynamics.
Key Terms
biomarker medical
gpu technical
gpu acceleration technical
AI-generated analysis. Not financial advice.
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -
- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -
KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.
Through its acquisition of Evoke Neuroscience, Inc. and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans.
The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,
“As demonstrated by this significant expansion of our commercial footprint and meaningful increase in our brain scan volumes, we continue to successfully execute against the key pillars of our growth strategy,” said Greg Lipschitz, Firefly’s Chief Executive Officer. “Our mission is to harness the power of AI and EEG/ERP to transform neuroscience and clinical development. With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the Company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
What growth did Firefly (AIFF) report on March 4, 2026?
How many EEG/ERP brain scans did Firefly (AIFF) complete in 2025?
What role does the Evoke Neuroscience acquisition play for Firefly (AIFF)?
Why is NVIDIA L40S GPU deployment important for Firefly (AIFF)?
What progress toward a foundation model did Firefly (AIFF) announce?
How large was Firefly's partner-site growth year-over-year as of end-2025?
